Clinical trial NCT03414112: The Impact of Oxytocin on the Neurobiology of Anorexia Nervosa
Official title: Investigating the Impact of Oxytocin on the Neurobiological Underpinnings of Socioemotional Deficits in Anorexia Nervosa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: Anorexia Nervosa
Lead sponsor: University of Minnesota
Sponsor class: OTHER
Collaborators: name: Klarman Foundation
First posted: 2018-01-29
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Participants with anorexia nervosa and age-matched control participants will complete two separate fMRI and test meal assessments: one following administration of intranasal oxytocin and one following placebo. The study will be double blind.
Primary purpose: OTHER

Brief summary: This study will use a randomized, controlled, double-blind design involving the administration of intranasal oxytocin (INOT) or placebo to adults with anorexia nervosa, restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli as well as eating behavior in a test meal paradigm.

Detailed description: The primary objective of this investigation is to determine the impact of oxytocin (OT), a peptide hormone that influences social affiliation, on socioemotional neural circuitry and eating disorder behavior in anorexia nervosa (AN). Because socioemotional processing deficits appear to play a key role in AN, OT is implicated as a potential biological mechanism by which eating disorder behavior (e.g., restrictive eating) is maintained. Used as a probe, intranasal oxytocin (INOT) provides an innovative method for examining the short-term impact of OT on socioemotional neural processing disturbances and eating disorder behavior in AN. The proposed study tests a theoretical model of the role of OT in the maintenance of AN by using an INOT probe to determine, and potentially alter, neurobiological responses to socioemotional stimuli. Specifically, this study will use a randomized, controlled, double-blind design involving the administration of INOT or placebo to adults with AN restricting subtype and age-matched controls prior to neuroimaging to assess the impact on frontolimbic brain activity in response to socioemotional stimuli. The potential impact of INOT on restrictive eating will also be assessed in a subsequent test meal. We predict that for participants with AN, INOT, but not placebo, will normalize frontolimbic activation in response to social reward stimuli and prefrontal activation in response to social threat stimuli. In addition, the investigators predict that AN participants will display reduced restrictive eating in a test meal paradigm following INOT (but not placebo) administration. Finally, investigators predict that changes in restrictive eating following INOT administration will be mediated by altered frontolimbic responding to socioemotional cues. This investigation will provide an essential link uniting the data supporting the importance of socioemotional processing deficits in AN with the emerging role of INOT in altering the neural circuits involved in social behavior to test an innovative neurobiological maintenance model of AN.

Eligibility criteria: Inclusion Criteria:

* All participants:

  1. Age \> 18 years old
  2. Female (given the potential sex differences to endogenous OT to INOT)
  3. Ability to read and speak in English
  4. Right-handed
* Anorexia nervosa participants:

  1. DSM-5 diagnosis of AN, restricting subtype (established by the SCID-5-RV),
  2. BMI \< 18.5 kg/m2 within the past month

     Exclusion Criteria:

     All participants

  <!-- -->

  1. Medical instability or current pregnancy or lactation
  2. Current substance use disorder, psychosis, or bipolar-I disorder
  3. Contraindication for fMRI (e.g., implanted metal)
  4. History of neurological disorder/injury (e.g., stroke; head injury with \> 10 minutes loss of consciousness)
  5. Food allergy that cannot be accommodated through substitutions to the laboratory test meal
  6. Lacking capacity to consent
  7. Contraindications for intranasal oxytocin administration
  8. Acute suicidality
  9. Psychoactive medication (e.g., antidepressants, antipsychotics)

     Exclusion for participants without anorexia nervosa

  <!-- -->

  1. Current DSM-5 Axis-I diagnosis or current or past eating disorder diagnosis
  2. BMI \< 19.0

Primary outcomes:
measure: Test meal
timeFrame: Following intranasal oxytocin or placebo (within 1-3 hours)
measure: fMRI measures
timeFrame: Following intranasal oxytocin or placebo administration (within 1-3 hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota - Dept of Psychiatry
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: Carol B Peterson, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Minnesota
name: Ann F Haynos, PhD
role: PRINCIPAL_INVESTIGATOR
References: